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Voluntary counselling, HIV testing and adjunctive
cotrimoxazole reduces mortality in tuberculosis patients
in Thyolo, Malawi
Rony Zachariah, Marie-Paule L. Spielmann, Christina Chinjia,
Patrick Gomanib,e, Victor Arendtc, Nicola J. Hargreavesd,e,
Felix M. Salaniponie and Anthony D. Harriese
Objectives: To assess the feasibility and effectiveness of voluntary counselling, HIV
testing and adjunctive cotrimoxazole in reducing mortality in a cohort of tuberculosis
(TB)patientsregisteredunderroutineprogrammeconditionsinaruraldistrictofMalawi.
Design: ‘Before’ and ‘after’ cohort study using historical controls.
Methods: Between 1 July 1999 and 30 June 2000 all TB patients were started on
standardized anti-TB treatment, and offered voluntary counselling and HIV testing
(VCT). Those found to be HIV-positive were offered cotrimoxazole at a dose of 480 mg
twice daily, provided there were no contraindications. Side-effects were monitored
clinically. End-of-treatment outcomes in this cohort (intervention group) were com-
pared with a cohort registered between 1 July 1998 and 30 June 1999 in whom VCT
and cotrimoxazole was not offered (control group).
Findings: A total of 1986 patients was registered in the study: 1061 in the intervention
group and 925 in the control cohort. In the intervention group, 1019 (96%) patients
were counselled pre-test, 964 (91%) underwent HIV testing and 938 (88%) were
counselled post-test. The overall HIV-seroprevalence rate was 77%. A total of 693
patients were given cotrimoxazole of whom 14 (2%) manifested minor dermatological
reactions. The adjusted relative risk of death in the intervention group compared with
the control group was 0.81 (P , 0.001). The number needed to treat with VCT and
adjunctive cotrimoxazole to prevent one death during anti-TB treatment was 12.5.
Interpretation: This study shows that VCT and adjunctive cotrimoxazole is feasible,
safe and reduces mortality rates in TB patients under routine programme conditions.
& 2003 Lippincott Williams & Wilkins
AIDS 2003, 17:1053–1061
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Introduction
Death rates in patients treated for tuberculosis (TB) in
sub-Saharan Africa have risen in the last 10–15 years,
the most important reason being concomitant HIV
infection [1]. Between 20 and 30% of HIV-infected
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within 12 months of starting treatment, with even
higher death rates reported in those with smear-nega-
tive PTB and extrapulmonary TB (EPTB) [1].
Infections are an important cause of the high morbidity
and mortality experienced by HIV-positive TB patients
during treatment [2–4], and it is believed that inter-
ventions to prevent these infections might improve
survival. Between 1995 and 1998, a cotrimoxazole
(sulphamethoxazole trimethoprim ﬁve/one) placebo
controlled trial in HIV-positive smear-positive PTB
patients in Cote d’Ivoire showed a 48% reduction in
deaths in the cotrimoxazole group [5]. The results of
this study were an important factor in persuading
WHO/UNAIDS to issue provisional recommendations
that cotrimoxazole be given to all patients in Africa
living with AIDS (by deﬁnition this includes HIV-
positive patients with TB) [6].
Malawi, a small country in central-southern Africa, is
currently experiencing a severe epidemic of HIV
infection, linked to which is a twin epidemic of TB. In
2000, a countrywide survey found that 77% of new
patients registered with TB were HIV-seropositive [7].
The National Tuberculosis Control Programme (NTP)
has reported rising death rates in new patients with
smear-positive PTB, and in 1998 the country had the
highest death rates reported in Africa [8]. Despite the
encouraging results from Cote d’Ivoire, it is uncertain
whether cotrimoxazole will have the same efﬁcacy in
Malawi because of differing resistance proﬁles of
commonly occurring pathogens [9]. The NTP in
consultation with the Ministry of Health and Popula-
tion concluded that there needed to be more evidence
to support a policy of widespread implementation of
adjunctive cotrimoxazole for patients with AIDS, in-
cluding those with TB.
The recommendations from WHO/UNAIDS [6] have
made it difﬁcult to ethically justify further efﬁcacy
studies using placebo controls. A district initiative was
therefore planned with the aim of assessing the feasi-
bility and effectiveness of voluntary counselling, HIV
testing and adjunctive treatment with cotrimoxazole in
reducing death rates in TB patients, who are registered
and treated under routine conditions. The objectives of
the study were: (i) to assess the feasibility of introducing
voluntary counselling and HIV testing (VCT) within a
TB control programme setting; (ii) to determine
whether adjunctive cotrimoxazole is safe; (iii) to mea-
sure death rates in a cohort of patients offered the
package of VCT followed by adjunctive cotrimoxazole
to those who were HIV-seropositive (intervention
group); and (iv) to compare results with those obtained
in a cohort of patients registered for TB in the previous
year when no VCT or cotrimoxazole was offered
(control group).
Methods
Setting and study design
The study was carried out in Thyolo District, in
Southern Malawi, with a population of 650 000. The
district has one government hospital, a mission hospital,
and 18 health centres which are involved in TB control
activities. The design was a ‘before’ and ‘after’ cohort
study measuring end-of-treatment death rates in a
group of TB patients offered an intervention package
compared with historical controls who were not
offered the intervention package in the previous year.
Diagnosis, registration and treatment of patients
with TB
The same standardized methods of diagnosing, register-
ing and treating patients with TB were used for the
intervention and control groups. Diagnosis, registration
and treatment of TB was carried out according to
National guidelines [10]. The different anti-TB treat-
ment regimens and their indications are shown in
Table 1. The initial phase of treatment was always
administered in hospital, and the continuation phase in
the community.
Integrated voluntary counselling and testing
services
In order to set-up voluntary counselling and HIV
testing services, a new counselling unit (comprising a
reception room, two counselling rooms and a waiting
area) was constructed. Four full-time counsellors and
an additional laboratory technician were also employed.
The necessary consumables for performing rapid HIV
tests were made available on a continuing basis.
Study populations
Intervention group
Between 1 July 1999 and 30 June 2000, all TB patients
who were registered in Thyolo district, at either the
government hospital or the mission hospital, were
enrolled into the VCT and adjunctive cotrimoxazole
treatment study. This cohort of patients was known as
the ‘intervention group’. All patients were registered
and started on standardized anti-tuberculosis treatment,
and referred to the hospital HIV-voluntary counselling
and testing unit. Patients were offered pre-test counsel-
ling, and those who accepted HIV testing were offered
post-test counselling. All blood samples were screened
for HIV-1 and HIV-2 using a combination of the
Capillus (Cambridge Diagnostics Ltd, Galway, Ireland)
and HIV-Spot (Genelabs Diagnostics, Singapore Sci-
ence Park, Singapore) tests. Any discordant sample was
retested, and if it remained discordant was sent for
ELISA testing at the referral hospital in Blantyre.
Patients who tested HIV-seropositive were offered
adjunctive cotrimoxazole, provided there were no
contraindications to the medication. Contraindications
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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pregnancy, breast-feeding until 2 months and children
aged less than 2 years (because of uncertainty about
HIV-serostatus). Cotrimoxazole was given at a dose of
480 mg (400 mg sulphamethoxazole and 80 mg tri-
methoprim) twice daily for the whole course of anti-
TB treatment and indeﬁnitely thereafter. Anti-TB
drugs and both daily doses of cotrimoxazole were
administered by direct observation during the initial
phase of treatment. In the continuation phase, anti-TB
drugs and cotrimoxazole were given to patients at
monthly intervals from their nearest health facility and
the drugs were self-administered. Patients received
enough pills for 33 days, which included a 3-day safety
stock in case the patient was unable to attend the health
facility on the speciﬁed follow-up date.
Compliance with self-administered cotrimoxazole was
assessed in a cohort of TB patients who were attending
four of the TB follow-up centres during the continua-
tion phase (months 4–6) of anti-TB treatment [11].
Urine trimethoprim was measured using gas chromato-
graphy and mass spectrometry, and was detected in 87
(94%) of 93 TB patients in the cohort.
Side-effects of cotrimoxazole were monitored clini-
cally. A protocol for monitoring side-effects was devel-
oped, and all health personnel were trained on how to
manage side-effects. A standard reporting form was also
available at all health facilities in the district.
Control group
Between 1 July 1998 and 30 June 1999, all TB patients
who were registered in the same two hospitals in the
district were started on the same standardized anti-TB
treatment, and this cohort of patients was known as the
‘control group’. This group was not offered VCT or
cotrimoxazole prophylaxis, as the intervention had not
commenced during this period.
Treatment outcomes
All patients were followed to the end of treatment, and
outcomes were recorded according to standard guide-
lines [12]. Death was deﬁned as a death at any time
during the 8–12 months of treatment from whatever
cause. Month of death, default or transfer-out was
recorded in the ﬁle. End-of-treatment outcomes were
classiﬁed after cross-veriﬁcation of information con-
tained in TB registers, laboratory registers, medication
registers and treatment cards. Reliability of treatment
outcomes was veriﬁed by conducting independent
household visits on a random sample of 40 TB patients
from the intervention and control groups. All these
outcomes were conﬁrmed correct.
In 160 TB patients (88 in the control group and 72 in
the intervention group), information on treatment out-
comes was incomplete and cross-veriﬁcation was not
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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VCTand cotrimoxazole reduces TB mortality Zachariah et al. 1055possible for the following reasons: the treatment register
was not properly completed; the treatment card had
been misplaced at the health centre; the date of
treatment outcome was not indicated. In these patients,
an independent household visit was conducted at the
end of the study period in order to obtain a reliable
end-of-treatment outcome.
Statistical analysis
A previous cohort study in Zomba district, Southern
Malawi, had shown an end-of-treatment mortality of
30% in patients with all types of TB [13]. A sample
size of 748 patients in each group was calculated to
achieve a power of 90%, and to detect a 25%
reduction in end-of-treatment mortality (from 30 to
22.5%) with a type I error rate of 5%. This calculation
formed the basis of using a 12-month recruitment
period for each group.
Data was entered and analysed using EPI-INFO 6.0
and 2000 (Centre for Disease Control and Prevention,
Atlanta Georgia, USA). Baseline characteristics of pa-
tients in the intervention and control groups were
compared using the chi-squared test for categorical
variables. Analysis of treatment outcome was carried
out between the intervention and control groups
according to the intention-to-treat principle. All pa-
tients were included in the intervention group regard-
less of whether they were treated with cotrimoxazole
or not. Differences in end-of-treatment outcomes be-
tween intervention and control groups were compared
using the chi-squared test. The relative risk of death
was stratiﬁed for type and category of TB as well as
anti-TB treatment using the Mantel–Haenszel chi-
squared test. Hazard ratios were also used to compare
death rates in the two groups per 100 person-months
of follow-up, and were stratiﬁed in the same way.
Overall survival distributions for both groups were
estimated using the Kaplan–Meier method and com-
pared using the Cox–Mantel (log-rank) test. All P
values were two sided, and the level of signiﬁcance was
set at P ¼ 0.05 or less. 95% Conﬁdence intervals (CI)
were used throughout.
Results
Characteristics of the study population
A total of 1986 patients was registered in the study:
1061 in the intervention group and 925 in the control
group. Characteristics of the two groups are shown in
Table 2. The age, sex and hospital at which the patients
were registered were similar between the two groups,
but the groups differed in terms of type and category of
TB, and in terms of anti-TB treatment.
Occupation and physical status on admission were
recorded in the intervention group only. The most
common occupations were farming in 625 (59%),
unskilled work in 173 (16%), business in 71 (7%) and
skilled work in 60 (6%) patients. On admission, 231
(22%) patients were moribund (bedridden and unable
to stand without support), 703 (66%) felt ill due to
clinical symptoms linked to TB/HIV, 87 (8%) felt well
and the physical status was unknown in 40 (4%)
patients.
VCTand adjunctive treatment with
cotrimoxazole
Of 1061 patients registered for TB in the intervention
group, 1019 (96%) were counselled pre-test, 964 (91%)
underwent HIV testing and 938 (88%) were counselled
post-test (Fig. 1). Of the 964 TB patients who were
tested for HIV, 740 (77%) were HIV positive: this
included 294(68%) patients with smear-positive PTB,
223 (86%) with smear-negative PTB and 223 (82%)
with EPTB.
Six-hundred and ninety-three patients, comprising 93%
of all known HIV positive cases and 65% of all
registered TB patients, were given cotrimoxazole after
a median of 4 days (range, 1–57 days) from registra-
tion. Two-hundred and eighty-three (61%) of 464
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 2. Characteristics of patients in the intervention (cotrimoxa-
zole) and control groups.
Cotrimoxazole
[n (%)]
Control
[n (%)] Pa
Total 1061 925
Median age (years) 32 (range 1–93) 31 range (1–85)
Age-group (in years)
1–14 85 (8) 81 (9) 0.5
15–44 783 (74) 689 (74) 0.7
45–64 169 (16) 141 (15) 0.7
. 64 24 (2) 14 (2) 0.2
Male 505 (48) 472 (51) 0.1
Site of registration
District Hospital 616 (58) 569 (62) 0.1
Mission Hospital 445 (42) 356 (38) 0.1
TB type
Smear-positive PTB 464 (44) 340 (37) , 0.01
Smear-negative PTB 282 (26) 288 (31) 0.02
EPTB 315 (30) 297 (32) 0.2
TB category
New TB case 967 (91) 897 (97) , 0.01
Relapse 39 (4) 22 (2) 0.09
Other 55 (5) 6 (1) , 0.01
Type of TB treatment
Short-course 542 (51) 400 (43) , 0.01
Standard treatment 350 (33) 416 (45) , 0.01
Retreatment 77 (7) 24 (3) , 0.01
TB meningitis 21 (2) 11 (1) 0.2
Paediatric 71 (7) 74 (8) 0.3
aChi-squared test. TB, Tuberculosis; PTB, pulmonary TB; EPTB, extra-
pulmonary TB.
AIDS 2003, Vol 17 No 7 1056registered patients with smear-positive PTB, 200 (71%)
of 282 patients with smear-negative PTB and 210
(67%) of 315 patients with EPTB were given cotri-
moxazole.
Reactions to cotrimoxazole
Of 693 patients on cotrimoxazole, 14 (2%) had a
dermatological reaction. No reactions were serious or
involved mucosal membranes, and all were reversible on
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
All newly registered TB patients
from July 1999 to June 2000
n  1061
42 not pre-test counselled
1019 counselled pre-test
55 HIV test not done
964 HIV test done
224 HIV negative 740 HIV positive
5 not counselled post-test 21 not counselled post-test
219 post-test counselled 719 post-test counselled
39 not on cotrimoxazole
693 placed on cotrimoxazole
(93% of all HIV positives)
9 died
9 refused
19 missed
2 absconded
3 transferred
9 died
44 refused
1 absconded
1 transferred
5 died
6 died
2 transferred out
[13 refused to know results
but accepted cotrimoxazole]
8 known allergy
5 pregnancy
3 lactation
16 less than 2 years
7 died
Fig. 1. Study proﬁle of tuberculosis patients in the intervention (cotrimoxazole) group.
VCTand cotrimoxazole reduces TB mortality Zachariah et al. 1057discontinuing treatment. All dermatological reactions
occurred in the ﬁrst 2 months of treatment, with 9
(64%) occurring during the ﬁrst month. In 13 patients
cotrimoxazole was discontinued indeﬁnitely, and in one
patient it was re-started (by mistake) without problems.
End-of-treatment outcomes and mortality rates
End-of-treatment outcomes in the intervention and
control groups – death, treatment success and other
outcomes – for all patients and in relation to type,
category of TB and treatment regimen are shown in
Table 3. Treatment outcomes were known for all
except seven patients in the control group.
Death was signiﬁcantly decreased for all patients in the
intervention group, and also for those with smear-
negative PTB, new TB and those on standard treat-
ment. Treatment success was also signiﬁcantly increased
for all patients in the intervention group, and for those
with smear-negative PTB, EPTB, new TB and those
on standard anti-TB treatment. For smear-positive
PTB patients, neither death nor treatment success were
signiﬁcantly different between the intervention and the
control groups. Other outcomes were similar between
the two groups for all patients except those with new
TB. The crude relative risk (RR) of death by the end
of treatment in the intervention compared with the
control group was 0.78 (95% CI, 0.69–0.89; P ,
0.001). Adjusted for type and category of TB as well as
anti-TB treatment, the RR was 0.81 (95% CI, 0.75–
0.87; P , 0.001).
Death rates per 100 person-months of follow-up and
the hazard ratios (HR) in the two groups for all patients
and in relation to type, category of TB and anti-TB
treatment were also calculated. Results were similar to
those obtained using death at the end of treatment as
the measurable outcome. The death rate for all regis-
tered TB patients was 4.0 per 100 person-months of
follow-up in the intervention group and 5.3 in the
control group, which corresponds to a 25% reduction
in risk of death (95% CI, 12.3–35.8). Adjusted for type
and category of TB as well as anti-TB treatment, the
HR was 0.76 (95% CI, 0.69–0.83).
Survival curves for both intervention and control
groups are shown in Fig. 2. By the end of the ﬁrst
month of treatment, 113 (38%) of 299 deaths had
occurred in the intervention group which was not
different from the 130 (39%) of 333 deaths in the
control group. These results were similar in patients
with different types of TB. A signiﬁcant difference in
the survival curve between the intervention and con-
trol groups became apparent from 4 months of anti-TB
treatment (Log-Rank test, P ¼ 0.05), and the overall
end-of-treatment survival probability was higher in the
intervention group compared with the control group.
In the intervention group receiving VCT and cotri-
moxazole 299 deaths (28% of 1061) occurred, whereas
333 deaths (36% of 925) occurred in the control group.
The number of TB patients needed to treat with a
package of VCT and adjunctive cotrimoxazole to
prevent one death during the course of anti-TB
treatment is 12.5.
Discussion
This study shows that a package of VCT and cotrimox-
azole given as adjunctive treatment to those who were
HIV-positive reduced the overall mortality in a cohort
of TB patients registered under routine programme
conditions in a rural district in Malawi. The interven-
tion appeared to be safe with minimal side-effects. The
protective effectiveness of this intervention package
was seen mainly in new patients (who comprised
. 90% of patients in both groups), and in patients with
smear-negative PTB and EPTB. There was no signiﬁ-
cant beneﬁt in patients with smear-positive PTB.
This was an operational research study using historical
controls as the comparison group, as a randomized
control trial was not possible. The use of historical
controls inevitably leads to problems in deciding what
really caused the reduction in mortality. Was it the
package of VCT, cotrimoxazole, increased enthusiasm
of the programme, the possibility that HIV-positive
patients look after themselves better than patients who
do not know their HIV-serostatus or that poverty
indicators were better in the intervention year com-
pared with the control year? We do not think that
poverty, care or programme enthusiasm were any
different between the two years, but we do not have
ﬁrm data to substantiate this.
Although the historical control group was similar in
age and sex to the intervention group, there were
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Fig. 2. Kaplan–Meier survival probability in the interven-
tion (cotrimoxazole) and control groups.
AIDS 2003, Vol 17 No 7 1058differences in the proportions of patients according to
type and category of TB. Towards the beginning of
the intervention period, the NTP had found that
patients with recurrent smear-negative TB were being
misclassiﬁed as new cases of TB [14]. These mistakes
were rectiﬁed, and this probably explains the increase
in TB cases registered as ‘other’. The increase in
proportion of patients with smear-positive PTB in the
intervention group reﬂects the on-going training and
supervision of all TB programme staff around Malawi
in improving the diagnosis of TB by sputum smear
examination.
Otherwise, the methods of diagnosing and registering
TB patients and the anti-TB treatment regimens were
the same in both study periods. HIV sero-status was
not measured in historical controls. Malawi has wit-
nessed escalating rates of HIV infection in its registered
TB patients during the 1990s [7]. Thus, if anything,
HIV-seroprevalence might have been higher in the
intervention group, which would have had the effect
of increasing mortality rates.
The strengths of this study are that a large number of
patients were registered in each of the study groups.
Rigorous attempts were made to accurately determine
end-of-treatment outcomes and month of death/default
or transfer-out. End-of-treatment outcomes were
known for all patients, except seven in the control
group. Default and transfer-out rates were low and in
general were similar in the two groups. The study also
used the routine district health services for implementa-
tion of activities, and the results are therefore relevant,
practicable and probably replicable in other parts of the
country.
The beneﬁt of cotrimoxazole was seen in the whole
cohort of TB patients, but when subgroup analysis was
performed the beneﬁt was only apparent in those with
smear-negative PTB and EPTB. The lack of effect in
patients with smear-positive PTB appears to conﬂict
with the results of the Cote d’Ivoire study [5]. There
are several possible reasons for these differences. First,
only 61% of smear-positive PTB patients were given
cotrimoxazole compared with 71% of patients with
smear-negative PTB. This might reduce the cohort
beneﬁt of cotrimoxazole in the smear-positive PTB
patients. Second, in Cote d’Ivoire, cotrimoxazole had
the most signiﬁcant effect on mortality in those most
immunosuppressed [5]. This effect has also been shown
in other parts of Africa [15]. HIV-infected patients with
smear-negative PTB may be more immunosuppresed
than those with smear-positive PTB [16], and thus
might be expected to beneﬁt more from cotrimoxa-
zole. Third, patients in our study were offered cotri-
moxazole as soon as possible after registration and
starting anti-TB treatment. This contrasts with the
design in Cote d’Ivoire [5] where patients were offered
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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VCTand cotrimoxazole reduces TB mortality Zachariah et al. 1059cotrimoxazole 1 month after starting anti-TB treat-
ment. We have already documented high early mortal-
ity rates in TB patients in Malawi, with nearly 40% of
deaths countrywide occurring in the ﬁrst month of
anti-TB treatment [17]. In the current study, a similar
high proportion of deaths in both intervention and
control groups occurred during the ﬁrst month, which
would negate the overall beneﬁt of cotrimoxazole.
Finally, differing patterns of HIV-related disease and
differing rates of cotrimoxazole resistance may reduce
the efﬁcacy of cotrimoxazole in our patients. There are
high rates of in vitro cotrimoxazole resistance to a wide
range of pathogens in Malawi [9]. Unfortunately we
have limited data on the pattern of HIV-related patho-
gens in Malawi [18], and this aspect was not investi-
gated in our study.
In addition to providing HIV-positive patients with an
effective prophylactic intervention, this study also
shows that HIV-counselling and testing is feasible
under routine conditions in a rural district and has a
high patient acceptance rate. HIV-counselling and test-
ing has been shown in sub-Saharan Africa to promote
behaviour change and safer sexual practices, and it
appears to be a cost-effective intervention to reduce
sexual transmission of HIV [19,20]. Patient compliance
with cotrimoxazole prophylaxis in the continuation
phase of anti-TB treatment (where the drug is self-
administered) was found to be encouragingly high [11].
Since June 2000, the package of VCT and cotrimox-
azole prophylaxis has continued in Thyolo district, and
good links have been established between the hospital
counselling services and community care groups.
Although cotrimoxazole had a signiﬁcant beneﬁt, the
death rates in patients offered this intervention were
still high. The feasibility and effectiveness of other
interventions to reduce early mortality (for example,
improving access to care, empirical use of antibiotics to
treat presumptive bacteraemia and use of cortico-
steroids) and to improve overall survival, including the
possible use of antiretroviral treatment, needs to be
explored [21].
For every 12.5 TB patients in our setting, that were
offered the package of VCT plus cotrimoxazole, there
was one preventable death during the course of anti-
TB treatment. Assuming the same level of uptake of
VCT countrywide, if the intervention package was
adopted by the NTP there might be just over 2000
prevented deaths during anti-TB treatment. In addi-
tion, VCT might lead to changes in sexual behaviour
and a reduction in HIV transmission. It has, however,
been suggested that widespread use of cotrimoxazole
for HIV-positive TB patients may increase the risk of
drug resistance for the treatment of acute respiratory
infections in children (cotrimoxazole is ﬁrst-line
therapy) and for treatment of malaria (sulphadoxine-
pyrimethamine is ﬁrst-line therapy) [22]. The policy
debate about whether to introduce the intervention
package will have to take into account these considera-
tions. Other issues include: given the high HIV-
seroprevalence, whether adjunctive cotrimoxazole
should be provided to all TB patients if widespread
implementation of VCT is slow; whether the interven-
tion should include all TB patients or just those with
smear-negative PTB and EPTB; and who has responsi-
bility for drug administration, adherence and costs after
anti-TB treatment.
Whatever the outcome of this debate, providing VCT
and adjunctive cotrimoxazole to TB patients is an
essential step to reduce the high mortality associated
with HIV infection in sub-Saharan Africa. Our ﬁndings
have important public health implications for TB
control in Malawi and in other high HIV-TB burden
countries of sub-Saharan Africa.
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